Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:LABPNASDAQ:PVLANASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.53-4.9%$3.60$2.30▼$8.40$277.57M1.141.80 million shs894,957 shsLABPLandos Biopharma$22.93+0.6%$22.54$2.50▼$22.94$71.77M0.1419,700 shs50,800 shsPVLAPalvella Therapeutics$27.18-6.3%$16.86$6.20▼$29.27$304.99M0.5452,858 shs46,277 shsTERNTerns Pharmaceuticals$3.45-5.7%$4.35$3.24▼$11.40$293.04M-0.31.39 million shs812,429 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-0.37%-3.62%-21.76%-41.02%-42.05%LABPLandos Biopharma0.00%0.00%0.00%0.00%+251.15%PVLAPalvella Therapeutics+3.61%+29.81%+84.48%+2,899,999,900.00%+2,899,999,900.00%TERNTerns Pharmaceuticals+5.17%+0.83%-17.94%-44.46%-48.67%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.0757 of 5 stars3.51.00.00.02.61.70.6LABPLandos BiopharmaN/AN/AN/AN/AN/AN/AN/AN/APVLAPalvella Therapeutics3.5827 of 5 stars4.50.00.00.03.12.50.6TERNTerns Pharmaceuticals4.0666 of 5 stars3.32.00.04.12.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$15.80524.51% UpsideLABPLandos Biopharma 2.00Hold$20.42-10.95% DownsidePVLAPalvella Therapeutics 3.00Buy$42.7557.28% UpsideTERNTerns Pharmaceuticals 2.67Moderate Buy$18.30430.43% UpsideCurrent Analyst Ratings BreakdownLatest LABP, ANNX, TERN, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2025PVLAPalvella TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$50.003/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/28/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform2/26/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$39.00 ➝ $39.002/20/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$39.002/11/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.002/5/2025PVLAPalvella TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$44.001/10/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.001/3/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.0012/26/2024PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$38.0012/18/2024PVLAPalvella TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/ALABPLandos Biopharma$18M3.99N/AN/A$7.41 per share3.09PVLAPalvella Therapeutics$42.81M7.12N/AN/A$21.66 per share1.25TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%3/25/2025 (Estimated)LABPLandos Biopharma-$21.93M-$3.99N/AN/AN/AN/A-73.00%-63.00%N/APVLAPalvella Therapeutics-$24.54M-$12.10N/AN/AN/AN/A-80.93%-59.55%3/27/2025 (Estimated)TERNTerns Pharmaceuticals-$90.21M-$1.18N/AN/AN/AN/A-32.76%-31.33%3/13/2025 (Estimated)Latest LABP, ANNX, TERN, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/4/2025N/APVLAPalvella Therapeutics-$0.39N/AN/AN/AN/AN/A3/27/2025N/APVLAPalvella Therapeutics-$0.5833N/AN/AN/AN/AN/A3/25/2025N/AANNXAnnexon-$0.28N/AN/AN/AN/AN/A3/13/2025N/ATERNTerns Pharmaceuticals-$0.30N/AN/AN/AN/AN/A3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18LABPLandos BiopharmaN/A4.434.43PVLAPalvella TherapeuticsN/A4.824.82TERNTerns PharmaceuticalsN/A32.9932.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ALABPLandos Biopharma49.06%PVLAPalvella Therapeutics40.11%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%LABPLandos Biopharma1.30%PVLAPalvella Therapeutics6.39%TERNTerns Pharmaceuticals15.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableLABPLandos Biopharma193.13 million3.09 millionNot OptionablePVLAPalvella TherapeuticsN/A11.22 million10.50 millionN/ATERNTerns Pharmaceuticals4084.94 million72.11 millionNot OptionableLABP, ANNX, TERN, and PVLA HeadlinesRecent News About These CompaniesTerns Pharmaceuticals (TERN) Expected to Announce Quarterly Earnings on ThursdayMarch 11 at 2:51 AM | americanbankingnews.comThis Weight Loss Stock Could Skyrocket by 462%, According to Wall StreetMarch 9, 2025 | fool.comCandriam S.C.A. Buys New Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)March 8, 2025 | marketbeat.comTerns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on ThursdayMarch 6, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Rating of "Moderate Buy" from BrokeragesMarch 5, 2025 | americanbankingnews.comTerns Pharmaceuticals (NASDAQ:TERN) Research Coverage Started at William BlairMarch 3, 2025 | americanbankingnews.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by AnalystsMarch 1, 2025 | marketbeat.comWilliam Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)March 1, 2025 | marketbeat.comTerns Pharmaceuticals initiated with a Market Perform at William BlairMarch 1, 2025 | markets.businessinsider.comWilliam Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform RecommendationMarch 1, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Vericel (VCEL) and Terns Pharmaceuticals (TERN)February 27, 2025 | markets.businessinsider.comIts CEO died. The company scrapped a promising program. Now, for their 2nd act.February 26, 2025 | finance.yahoo.comTerns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)February 26, 2025 | globenewswire.comTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial OfficerFebruary 25, 2025 | finanznachrichten.deTerns Pharmaceuticals sees cash runway into 2028February 25, 2025 | markets.businessinsider.comMizuho Securities Remains a Buy on Terns Pharmaceuticals (TERN)February 25, 2025 | markets.businessinsider.comTerns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare ConferenceFebruary 25, 2025 | globenewswire.comTerns Pharmaceuticals appoints Andrew Gengos as CFOFebruary 24, 2025 | markets.businessinsider.comTerns Pharmaceuticals Appoints Andrew Gengos as Chief Financial OfficerFebruary 24, 2025 | globenewswire.comTerns Pharmaceuticals Appoints Robert Azelby to Board of DirectorsFebruary 20, 2025 | globenewswire.comTerns Pharmaceuticals stock hits 52-week low at $4.16February 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesVolatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsBy Gabriel Osorio-Mazilli | February 27, 2025View Volatility Is Back: 3 Stocks To Cushion the S&P 500's Swings3 Tech Stocks Defying Sector Weakness and Thriving in 2025By Leo Miller | March 10, 2025View 3 Tech Stocks Defying Sector Weakness and Thriving in 2025GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss TrendsBy Jea Yu | February 12, 2025View GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss TrendsATN International: A Deep Value Play With a High-Powered DividendBy Nathan Reiff | February 17, 2025View ATN International: A Deep Value Play With a High-Powered DividendShopify Confirms Stock Uptrend, New Highs in SightBy Thomas Hughes | February 12, 2025View Shopify Confirms Stock Uptrend, New Highs in SightLABP, ANNX, TERN, and PVLA Company DescriptionsAnnexon NASDAQ:ANNX$2.53 -0.13 (-4.89%) Closing price 04:00 PM EasternExtended Trading$2.48 -0.05 (-2.17%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Landos Biopharma NASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.Palvella Therapeutics NASDAQ:PVLA$27.18 -1.82 (-6.28%) As of 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Terns Pharmaceuticals NASDAQ:TERN$3.45 -0.21 (-5.74%) Closing price 04:00 PM EasternExtended Trading$3.49 +0.04 (+1.16%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount? Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Market Overreacts, But Guidewire’s Growth Story Remains Strong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
